As researchers around the world work to discover a vaccine to prevent COVID-19, Indiana University School of Medicine has been selected as a site to test AZD1222, a vaccine being developed by biopharmaceutical company AstraZeneca, in partnership with Oxford University. This Phase III clinical trial is the last required stage of study before the potential vaccine can be approved by the Food and Drug Administration for widespread public use.
Read more about IU School of Medicine's selection as a test site for Phase III clinical trials